サマリー

当レポートでは、米国における好酸球性肉芽腫症の市場規模および予測を掲載しています。
米国好酸球性肉芽腫症市場収益、2016-2021年、2022-2027年、(百万ドル)
アメリカ合衆国好酸球性肉芽腫症市場売上高、2016-2021年、2022-2027年、(キロトン)
米国の好酸球性肉芽腫症企業トップ5社（2020年）(%)
好酸球性肉芽腫症の世界市場規模は、2020年のXX百万米ドルから2027年にはXX百万米ドルに成長すると予想され、2021-2027年の間にXX％のCAGRで成長すると予想されます。
米国の好酸球性肉芽腫症市場は、2020年にXX百万米ドルとなり、予測期間中にXX％のCAGRで2027年にXX百万米ドルに達すると予測されています。
QYResearchは、好酸球性肉芽腫症のメーカー、サプライヤー、流通業者、業界専門家を対象に、売上高、収益、需要、価格変動、製品タイプ、最近の開発と計画、業界動向、ドライバー、課題、障害、潜在的リスクなど、この業界に関する調査を行いました。
総市場をセグメント別に見ると
米国好酸球性肉芽腫症市場、タイプ別、2016年～2021年、2022年～2027年（単位：百万ドル）・（単位：キロトン）
米国好酸球性肉芽腫症市場セグメント比率、タイプ別、2020年(%)
経口
静脈注射
その他

米国好酸球性肉芽腫症市場、用途別、2016-2021年、2022-2027年 (百万ドル) & (キロトン)
米国好酸球性肉芽腫症市場セグメント別割合、アプリケーション別、2020年(%)
病院薬剤師
ドラッグストア
その他

競合他社の分析
本レポートでは、以下のような主要な市場参加者の分析も行っています。
主要企業 米国市場における好酸球性肉芽腫症の収益、2016-2021年（推定）、（百万ドル）
主要企業の好酸球性肉芽腫症の米国市場における収益シェア、2020年(%)
主要企業の好酸球性肉芽腫症の米国市場における売上高、2016-2021年（推定）、（Kiloton）
主要企業の好酸球性肉芽腫症の米国市場における売上高シェア、2020年(%)
さらに、本レポートでは、市場における競合他社のプロファイルを紹介しています。主要なプレイヤーは以下の通りです。
グラクソ・スミスクライン（GlaxoSmithKline
ファーマシューティカルズホールディングス
バクスター
ジェネンテック(ロシュ)
Cephalon(Teva)
アムジェン
サノフィ
DSM
アストラゼネカ
ノバルティス・インターナショナル

ページTOPに戻る

目次

1 Introduction to Research & Analysis Reports
1.1 Eosinophilic Granulomatosis Market Definition
1.2 Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
1.3 United States Eosinophilic Granulomatosis Market Overview
1.4 Methodology & Sources of Information
1.4.1 Research Methodology
1.4.2 Research Process
1.4.3 Base Year

2 United States Eosinophilic Granulomatosis Overall Market Size
2.1 United States Eosinophilic Granulomatosis Market Size: 2021 VS 2027
2.2 United States Eosinophilic Granulomatosis Revenue, Prospects & Forecasts: 2016-2027
2.3 United States Eosinophilic Granulomatosis Sales: 2016-2027

3 Company Landscape
3.1 Top Eosinophilic Granulomatosis Players in United States Market
3.2 Top United States Eosinophilic Granulomatosis Companies Ranked by Revenue
3.3 United States Eosinophilic Granulomatosis Revenue by Companies
3.4 United States Eosinophilic Granulomatosis Sales by Companies
3.5 United States Eosinophilic Granulomatosis Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Eosinophilic Granulomatosis Companies in United States Market, by Revenue in 2020
3.7 Manufacturers Eosinophilic Granulomatosis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Eosinophilic Granulomatosis Players in United States Market
3.8.1 List of Tier 1 Eosinophilic Granulomatosis Companies in United States
3.8.2 List of Tier 2 and Tier 3 Eosinophilic Granulomatosis Companies in United States

4 Sights by Type
4.1 Overview
4.1.1 By Type - United States Eosinophilic Granulomatosis Market Size Markets, 2021 & 2027
4.1.2 Oral
4.1.3 Intravenous
4.1.4 Others
4.2 By Type - United States Eosinophilic Granulomatosis Revenue & Forecasts
4.2.1 By Type - United States Eosinophilic Granulomatosis Revenue, 2016-2021
4.2.2 By Type - United States Eosinophilic Granulomatosis Revenue, 2022-2027
4.2.3 By Type - United States Eosinophilic Granulomatosis Revenue Market Share, 2016-2027
4.3 By Type - United States Eosinophilic Granulomatosis Sales & Forecasts
4.3.1 By Type - United States Eosinophilic Granulomatosis Sales, 2016-2021
4.3.2 By Type - United States Eosinophilic Granulomatosis Sales, 2022-2027
4.3.3 By Type - United States Eosinophilic Granulomatosis Sales Market Share, 2016-2027
4.4 By Type - United States Eosinophilic Granulomatosis Price (Manufacturers Selling Prices), 2016-2027

5 Sights by Application
5.1 Overview
5.1.1 By Application - United States Eosinophilic Granulomatosis Market Size, 2021 & 2027
5.1.2 Hospital Pharmacies
5.1.3 Drug Stores
5.1.4 Others
5.2 By Application - United States Eosinophilic Granulomatosis Revenue & Forecasts
5.2.1 By Application - United States Eosinophilic Granulomatosis Revenue, 2016-2021
5.2.2 By Application - United States Eosinophilic Granulomatosis Revenue, 2022-2027
5.2.3 By Application - United States Eosinophilic Granulomatosis Revenue Market Share, 2016-2027
5.3 By Application - United States Eosinophilic Granulomatosis Sales & Forecasts
5.3.1 By Application - United States Eosinophilic Granulomatosis Sales, 2016-2021
5.3.2 By Application - United States Eosinophilic Granulomatosis Sales, 2022-2027
5.3.3 By Application - United States Eosinophilic Granulomatosis Sales Market Share, 2016-2027
5.4 By Application - United States Eosinophilic Granulomatosis Price (Manufacturers Selling Prices), 2016-2027

6 Manufacturers & Brands Profiles
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Overview
6.1.3 GlaxoSmithKline Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.1.4 GlaxoSmithKline Eosinophilic Granulomatosis Product Description
6.1.5 GlaxoSmithKline Recent Developments
6.2 Pharmaceuticals Holdings
6.2.1 Pharmaceuticals Holdings Corporation Information
6.2.2 Pharmaceuticals Holdings Overview
6.2.3 Pharmaceuticals Holdings Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.2.4 Pharmaceuticals Holdings Eosinophilic Granulomatosis Product Description
6.2.5 Pharmaceuticals Holdings Recent Developments
6.3 Baxter
6.3.1 Baxter Corporation Information
6.3.2 Baxter Overview
6.3.3 Baxter Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.3.4 Baxter Eosinophilic Granulomatosis Product Description
6.3.5 Baxter Recent Developments
6.4 Genentech(Roche)
6.4.1 Genentech(Roche) Corporation Information
6.4.2 Genentech(Roche) Overview
6.4.3 Genentech(Roche) Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.4.4 Genentech(Roche) Eosinophilic Granulomatosis Product Description
6.4.5 Genentech(Roche) Recent Developments
6.5 Cephalon(Teva)
6.5.1 Cephalon(Teva) Corporation Information
6.5.2 Cephalon(Teva) Overview
6.5.3 Cephalon(Teva) Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.5.4 Cephalon(Teva) Eosinophilic Granulomatosis Product Description
6.5.5 Cephalon(Teva) Recent Developments
6.6 Amgen
6.6.1 Amgen Corporation Information
6.6.2 Amgen Overview
6.6.3 Amgen Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.6.4 Amgen Eosinophilic Granulomatosis Product Description
6.6.5 Amgen Recent Developments
6.7 Sanofi
6.7.1 Sanofi Corporation Information
6.7.2 Sanofi Overview
6.7.3 Sanofi Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.7.4 Sanofi Eosinophilic Granulomatosis Product Description
6.7.5 Sanofi Recent Developments
6.8 DSM
6.8.1 DSM Corporation Information
6.8.2 DSM Overview
6.8.3 DSM Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.8.4 DSM Eosinophilic Granulomatosis Product Description
6.8.5 DSM Recent Developments
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Overview
6.9.3 AstraZeneca Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.9.4 AstraZeneca Eosinophilic Granulomatosis Product Description
6.9.5 AstraZeneca Recent Developments
6.10 Novartis International
6.10.1 Novartis International Corporation Information
6.10.2 Novartis International Overview
6.10.3 Novartis International Eosinophilic Granulomatosis Sales and Revenue in United States Market (2016-2021)
6.10.4 Novartis International Eosinophilic Granulomatosis Product Description
6.10.5 Novartis International Recent Developments

7 United States Eosinophilic Granulomatosis Production Capacity, Analysis
7.1 United States Eosinophilic Granulomatosis Production Capacity, 2016-2027
7.2 Eosinophilic Granulomatosis Production Capacity of Key Manufacturers in United States Market

8 Key Market Trends, Opportunity, Drivers and Restraints
8.1 Market Opportunities & Trends
8.2 Market Drivers
8.3 Market Restraints

9 Eosinophilic Granulomatosis Supply Chain Analysis
9.1 Eosinophilic Granulomatosis Industry Value Chain
9.2 Eosinophilic Granulomatosis Upstream Market
9.3 Eosinophilic Granulomatosis Downstream and Clients
9.4 Marketing Channels Analysis
9.4.1 Marketing Channels
9.4.2 Eosinophilic Granulomatosis Distributors and Sales Agents in United States Market

10 Conclusion
11 Appendix
11.1 Note
11.2 Examples of Clients
11.3 Author Details
11.4 Disclaimer